Leukemia, Acute Lymphoblastic (ALL)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Leukemia, Acute Lymphoblastic

MalaCards integrated aliases for Leukemia, Acute Lymphoblastic:

Name: Leukemia, Acute Lymphoblastic 57 74 38
Acute Lymphoblastic Leukemia 12 75 53 59 29 6 15 17
Acute Lymphocytic Leukemia 12 75 53 59 43 15 72
All 57 53 59 74
Leukemia, Acute Lymphocytic, Susceptibility to, 1 57 13
Leukemia, Acute Lymphoblastic, Susceptibility to 29 6
B-Cell Acute Lymphoblastic Leukemia 37 17
Leukemia, Acute Lymphoblastic, Susceptibility to, 3 72
Precursor Cell Lymphoblastic Leukemia-Lymphoma 44
Precursor Cell Lymphoblastic Leukemia Lymphoma 72
Leukemia Acute Lymphoblastic B-Hyperdiploid 74
Childhood Acute Lymphoblastic Leukemia 74
Lymphoblastic Leukemia Acute Childhood 55
Acute Lymphoblastic Leukemia/lymphoma 59
Leukemia B-Cell Acute Lymphoblastic 74
Leukemia T-Cell Acute Lymphoblastic 74
Leukemia, Acute Lymphoblastic, 3 74
Leukemia, Lymphocytic, Acute, L1 72
Leukemia Acute Lymphoblastic 1 74
Leukemia, Acute, Lymphoblastic 40
Leukemia, Acute Lymphocytic 1 57
Leukemia Acute Lymphocytic 1 74
Lymphoblastic Leukemia Acute 55
Leukemia Acute Lymphocytic 74
All3 74
All1 74


Orphanet epidemiological data:

acute lymphoblastic leukemia
Prevalence: 1-9/100000 (France),1-9/100000 (United States),1-5/10000 (United States),1-5/10000 (Europe); Age of onset: All ages; Age of death: any age;


leukemia, acute lymphoblastic:
Inheritance polygenic inheritance


External Ids:

Disease Ontology 12 DOID:9952
OMIM 57 613065
KEGG 37 H00001
ICD9CM 35 204.0
MeSH 44 D054198
NCIt 50 C3167
SNOMED-CT 68 90151006 91857003
ICD10 33 C91.0 C91.00
ICD10 via Orphanet 34 C91.0
UMLS via Orphanet 73 C0023449
Orphanet 59 ORPHA513
UMLS 72 C0023449 C0023452 C1961102 more

Summaries for Leukemia, Acute Lymphoblastic

NIH Rare Diseases : 53 Acute lymphoblastic leukemia (ALL) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). It may develop in children or adults. ALL spreads to the blood fairly quickly, and then may spread to other areas of the body such as the lymph nodes, liver, spleen, central nervous system, and testicles (in males). Signs and symptoms of ALL may include fever, easy bruising or bleeding, feeling tired, loss of appetite, pain in the bones or abdomen, and painless lumps in the neck, underarm, stomach, or groin. ALL is typically caused by random, non-inherited changes in the DNA of immature lymphocytes called lymphoblasts. However, some people may inherit a genetic susceptibility to developing ALL. The risk to develop ALL may also be increased by past treatment for cancer, and by having certain genetic conditions or syndromes. Having one or more risk factors does not mean that a person definitely will develop ALL. Treatment of ALL depends on the person's age, how advanced the cancer is, and whether certain genetic changes are found in cancer cells. Treatment options may involve systemic and/or intrathecal chemotherapy, radiation therapy, targeted therapy, and/or a stem cell transplant. Biologic therapy and chimeric antigen receptor (CAR) T-cell therapy are currently being studied as treatment options and may be used when other therapies are not working. The chance of recovery also depends on many factors. With treatment, about 98% of children with ALL go into remission, and 85% of those with first-time ALL are expected have no long-term complications. The chance of recovery for adults is not as high, as 20-40% of adults are cured with current treatments.

MalaCards based summary : Leukemia, Acute Lymphoblastic, also known as acute lymphoblastic leukemia, is related to leukemia, acute lymphoblastic 3 and acute leukemia, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Leukemia, Acute Lymphoblastic is PAX5 (Paired Box 5), and among its related pathways/superpathways are Transcriptional misregulation in cancer and MicroRNAs in cancer. The drugs Micafungin and Posaconazole have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are acute lymphoblastic leukemia and neoplasm

Disease Ontology : 12 A lymphoblastic leukemia that is characterized by over production of lymphoblasts.

OMIM : 57 Acute lymphoblastic leukemia (ALL), also known as acute lymphocytic leukemia, is a subtype of acute leukemia, a cancer of the white blood cells. Somatically acquired mutations in several genes have been identified in ALL lymphoblasts, cells in the early stages of differentiation. Germline variation in certain genes may also predispose to susceptibility to ALL (Trevino et al., 2009). (613065)

MedlinePlus : 43 Leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, however, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. In acute lymphocytic leukemia (ALL), also called acute lymphoblastic leukemia, there are too many of specific types of white blood cells called lymphocytes or lymphoblasts. ALL is the most common type of cancer in children. Possible risk factors for ALL include being male, being white, previous chemotherapy treatment, exposure to radiation, and for adults, being older than 70. Symptoms of ALL include: Weakness or feeling tired Fever Easy bruising or bleeding Bleeding under the skin Shortness of breath Weight loss or loss of appetite Pain in the bones or stomach Pain or a feeling of fullness below the ribs Painless lumps in the neck, underarm, stomach, or groin Tests that examine the blood and bone marrow diagnose ALL. Treatments include chemotherapy, radiation therapy, stem cell transplants, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells. Once the leukemia is in remission, you need additional treatment to make sure that it does not come back. NIH: National Cancer Institute

KEGG : 37
Acute lymphocytic leukemia (ALL) is a clonal stem cell malignancy of excessive lymphoblast proliferation. It is now understood that ALL and lymphoblastic lymphoma are the same disease entities at the morphologic and immunophenotypic levels and classified as either B- and T-cell lymphoblastic leukemia/lymphoma (B-ALL and T-ALL). In the case of B-ALL, numerous reports have demonstrated that recurring genetic abnormalities are associated with sufficiently unique clinical, immunophenotypic, and/or prognostic features so that they can be considered as distinct entities. The most common rearrangements observed in B-ALL are the t(12;21) (p13;q22) rearrangement resulting in expression of the ETV6-RUNX1 fusion (TEL-AML1); the t(1;19) (q23;p13) translocation that results in expression of the TCF3 (E2A) fusion partner, (also known as TCF3) TFPT-PBX1 fusion (E2A-PBX); the t(9;22) (q34;q11.2) "Philadelphia" chromosome resulting in expression of the BCR-ABL1 fusion; and rearrangements of MLL (also known as KMT2A) at 11q23 to a diverse array of fusion partners. If none of these specific genetic abnormalities are found, the designation of "B lymphoblastic leukemia/lymphoma, not otherwise specified," is appropriate.

UniProtKB/Swiss-Prot : 74 Leukemia, acute lymphoblastic: A subtype of acute leukemia, a cancer of the white blood cells. ALL is a malignant disease of bone marrow and the most common malignancy diagnosed in children. The malignant cells are lymphoid precursor cells (lymphoblasts) that are arrested in an early stage of development. The lymphoblasts replace the normal marrow elements, resulting in a marked decrease in the production of normal blood cells. Consequently, anemia, thrombocytopenia, and neutropenia occur to varying degrees. The lymphoblasts also proliferate in organs other than the marrow, particularly the liver, spleen, and lymphnodes. Leukemia, acute lymphoblastic, 3: A subtype of acute leukemia, a cancer of the white blood cells. Acute lymphoblastic anemia is a malignant disease of bone marrow and the most common malignancy diagnosed in children. The malignant cells are lymphoid precursor cells (lymphoblasts) that are arrested in an early stage of development. The lymphoblasts replace the normal marrow elements, resulting in a marked decrease in the production of normal blood cells. Consequently, anemia, thrombocytopenia, and neutropenia occur to varying degrees. The lymphoblasts also proliferate in organs other than the marrow, particularly the liver, spleen, and lymphnodes.

Wikipedia : 75 Acute lymphoblastic leukemia (ALL) is a cancer of the lymphoid line of blood cells characterized by the... more...

Related Diseases for Leukemia, Acute Lymphoblastic

Diseases in the Leukemia, Acute Lymphoblastic family:

Leukemia, Acute Lymphoblastic 2 Leukemia, Acute Lymphoblastic 3

Diseases related to Leukemia, Acute Lymphoblastic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1225)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute lymphoblastic 3 35.6 PAX5 FLT3 ETV6
2 acute leukemia 32.0 PAX5 FLT3 ETV6
3 leukemia, acute myeloid 31.4 MIR223 MIR155 MIR128-1 FLT3 ETV6 CDKN2B-AS1
4 leukemia, chronic myeloid 31.3 MIR223 MIR203A FLT3 ETV6
5 hematologic cancer 31.3 XIST PAX5 FLT3 ETV6
6 oral squamous cell carcinoma 31.2 MIR223 MIR203A MIR155 MIR128-1
7 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 30.9 FLT3 ETV6
8 pancreatic cancer 30.8 XIST MIR223 MIR203A MIR155 CDKN2B-AS1
9 hepatocellular carcinoma 30.3 XIST MIR223 MIR203A MIR155 MIR152 CDKN2B-AS1
10 b-cell childhood acute lymphoblastic leukemia 13.0
11 adult acute lymphocytic leukemia 12.7
12 leukemia, acute lymphoblastic 2 12.6
13 b-cell adult acute lymphocytic leukemia 12.5
14 t-cell adult acute lymphocytic leukemia 12.5
15 acute lymphoblastic leukemia congenital sporadic aniridia 12.5
16 t-cell childhood acute lymphocytic leukemia 12.3
17 acute t cell leukemia 11.8
18 medulloblastoma 11.8
19 precursor lymphoblastic lymphoma/leukemia 11.8
20 lymphoblastic leukemia, acute, with lymphomatous features 11.5
21 pdgfra-associated chronic eosinophilic leukemia 11.4
22 prostate cancer 11.1
23 lymphocytic leukemia 11.1
24 leukemia 11.0
25 pancreatic ductal adenocarcinoma 10.9 MIR223 MIR203A MIR155
26 ovarian cancer 10.9 XIST NBN MIR223 MIR155 MIR152 CDKN2B-AS1
27 endometriosis 10.9 MIR223 MIR196B CDKN2B-AS1
28 neutrophilia, hereditary 10.8 MIR223 FLT3
29 bone marrow cancer 10.7 MIR155 FLT3 ETV6
30 chromosomal triplication 10.5
31 osteonecrosis 10.5
32 central nervous system leukemia 10.5
33 down syndrome 10.5
34 severe combined immunodeficiency 10.5
35 t-cell leukemia 10.5
36 lipid metabolism disorder 10.5
37 leukemia, t-cell, chronic 10.5
38 48,xyyy 10.4
39 retinoblastoma 10.4
40 wilms tumor 5 10.4
41 mucositis 10.4
42 testicular leukemia 10.4
43 central nervous system disease 10.4
44 familial retinoblastoma 10.4
45 nervous system disease 10.4
46 precursor t-cell acute lymphoblastic leukemia 10.4
47 bone mineral density quantitative trait locus 3 10.4
48 glucocorticoid resistance, generalized 10.4
49 neuropathy 10.4
50 acute graft versus host disease 10.4

Graphical network of the top 20 diseases related to Leukemia, Acute Lymphoblastic:

Diseases related to Leukemia, Acute Lymphoblastic

Symptoms & Phenotypes for Leukemia, Acute Lymphoblastic

Human phenotypes related to Leukemia, Acute Lymphoblastic:

# Description HPO Frequency HPO Source Accession
1 acute lymphoblastic leukemia 32 HP:0006721

Clinical features from OMIM:


UMLS symptoms related to Leukemia, Acute Lymphoblastic:

angina pectoris, edema, chest pain

MGI Mouse Phenotypes related to Leukemia, Acute Lymphoblastic:

# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.1 ACTB ETV6 FLT3 NBN PAX5 PMS2

Drugs & Therapeutics for Leukemia, Acute Lymphoblastic

DrugBank drugs 16 :

(show all 16)
# Drug Name Indication DrugBank ID
1 Asparaginase Erwinia chrysanthemi Asparaginase _Erwinia_ _chrysanthemi_ is for the treatment of patients with acute lymphoblastic leukemia (ALL) that have developed a hypersensitivity to E. coli-derivied asparaginase [L149]. It is a component of a multi-agent chemotherpeutic regimen [L149] for the treatment of the aforementioned disease and is considered second- or third- line treatment in European and American protocols [A7464]. DB08886
2 Asparaginase Escherichia coli Indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) [FDA Label]. DB00023
3 Calaspargase pegol This drug is is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years [FDA label]. The pharmacokinetics of calaspargase pegol were examined when given in combination with multiagent chemotherapy in 124 patients with B-cell lineage ALL [L4890]. The FDA approval of this drug was based on the achievement and maintenance of nadir serum asparaginase activity above the level of 0.1 U/mL when administering calaspargase, 2500 U/m2 intravenously, at 3-week intervals. DB14730
4 Cyclophosphamide Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients. DB00531
5 Cytarabine For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia. DB00987
6 Dasatinib For the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy. DB01254
7 Daunorubicin For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults. DB00694
8 Doxorubicin Doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer. DB00997
9 Etoposide For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme. DB00773
10 Mercaptopurine For remission induction and maintenance therapy of acute lymphatic leukemia. DB01033
11 Methotrexate Methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis.[L7144] Methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis.[L7147,L7150] Other formulations are indicated to treat gestational choriocarcinoma, chorioadenoma destruens, hydatiform mole, breast cancer, epidermoid cancer of the head and neck, advanced mycosis fungoides, lung cancer, and advanced non-Hodgkin's lymphoma.[L7180] It is also used in the maintenance of acute lymphocytic leukemia.[L7180] Methotrexate is also given before treatment with leucovorin to prolong relapse-free survival following surgical removal of a tumour in non-metastatic osteosarcoma.[L7180] DB00563
12 Mitoxantrone For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis DB01204
13 Pegaspargase For treatment of acute lymphoblastic leukemia DB00059
14 Ponatinib Ponatinib is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy. DB08901
15 Prednisone For the treatment of drug-induced allergic reactions, perennial or seasonal allergic rhinitis, serum sickness, giant cell arteritis acute rheumatic or nonrheumatic carditis, systemic dermatomyositis, systemic lupus erythematosus, atopic dermatitis, contact dermatitis, exfoliative dermatitis, bullous dermatitis herpetiformis, severe seborrheic dermatitis, severe (Stevens-Johnson syndrome) erythema multiforme, mycosis fungoides, pemphigus, severe psoriasis, acute adrenocortical insufficiency, Addison's disease, secondary adrenocortical insufficiency, congenital adrenal hyperplasia, hypercalcemia associated with neoplasms, nonsuppurative thyroiditis, ulceratice colitis, Crohn's disease, acquired hemolytic anemia, congenital hypoplastic anemia, erythroblastopenia, adult secondary thrombocytopenia, adult idiopathic thrombocytopenia purpura, acute or subacute bursitis, epicondylitis, acute nonspecific tenosynovitis, acute or chronic lymphocytic leukemia, Hodgkin's or non-Hodgkin's lynphomas, Waldenstrom's macroglobulinemia, primary brain tumors (adjunct), nephrotic syndrome, tuberculous meningitis, multiple sclerosis, myasthenia gravis. cerebral edema, chorioretinitis, diffuse posterior choroiditis, aleergic conjunctivitis, Herpes zoster ophthalmicus, anterior segment inflammation, iridocyclitis, iritis, keratitis, optoc neuritis, sympathetic ophthalmia, corneal marginal allergic ulcers, symptomatic sarcoidosis, Loeffler's syndrome not manageable by other means, berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy and aspiration pneumonitis. DB00635
16 Vincristine Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL). DB00541

Drugs for Leukemia, Acute Lymphoblastic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 592)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
Oprelvekin Approved, Investigational Phase 4 145941-26-0
Epirubicin Approved Phase 4 56420-45-2 41867
Decitabine Approved, Investigational Phase 4 2353-33-5 451668
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 23925 27284
Metformin Approved Phase 4 657-24-9 4091 14219
Nicotine Approved Phase 4 54-11-5 942 89594
Teniposide Approved Phase 4 29767-20-2 34698
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 6433735 5283731
14 Imatinib Mesylate Phase 4 220127-57-1 123596
15 Hormone Antagonists Phase 4
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
Ethylene Phase 4 74-85-1 6325
18 Liver Extracts Phase 4
19 Hypoglycemic Agents Phase 4
20 Iron Chelating Agents Phase 4
21 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
22 Micronutrients Phase 4
23 Vitamins Phase 4
24 Trace Elements Phase 4
25 Nutrients Phase 4
26 Vitamin D2 Phase 4
27 Ergocalciferols Phase 4
28 Calciferol Phase 4
29 Hydroxycholecalciferols Phase 4
30 Neurotransmitter Uptake Inhibitors Phase 4
31 Adrenergic Agents Phase 4
32 Atomoxetine Hydrochloride Phase 4
Mercaptopurine Approved Phase 3 50-44-2 667490
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
Etoposide Approved Phase 3 33419-42-0 36462
Rasburicase Approved, Investigational Phase 3 134774-45-1
Zoledronic Acid Approved Phase 3 118072-93-8 68740
Iodine Approved, Investigational Phase 3 7553-56-2 807
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
Calcium carbonate Approved, Investigational Phase 3 471-34-1
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
Etidronic acid Approved Phase 3 2809-21-4, 7414-83-7 3305
Risedronate Approved, Investigational Phase 3 105462-24-6 5245
Acyclovir Approved Phase 3 59277-89-3 2022
Ofloxacin Approved Phase 3 82419-36-1 4583

Interventional clinical trials:

(show top 50) (show all 1931)
# Name Status NCT ID Phase Drugs
1 Multicenter Study To Optimize Treatment in Elderly Patients (> 55 Years, No Upper Age Limit) With Acute Lymphoblastic Leukemia (GMALL Elderly 1/2003)(Amend 2) Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
2 Philadelphia -Negative High-risk Children Acute Lymphoblastic Leukemia(ALL) Treatment:Induction Therapy:Vincristine(V),Idarubicin(I),L-asparaginase(L),Dexamethasone(D);Consolidation:V+Daunorubicin(D)+L+D, Methotrexate,Cytarabine Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
3 German Multicenter Study for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years (Amend 3) (GMALL 07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
4 Ma-Spore ALL 2010 Study Unknown status NCT02894645 Phase 4 Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
5 PEG-asparaginase During Two Treatment Courses in the Treatment of Childhood Acute Lymphoblastic Leukemia Unknown status NCT00192673 Phase 4 PEG-asparaginase
6 Clinical Study of GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia in Guangdong Province Unknown status NCT00846703 Phase 4 6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
7 The Combination of Lower Dosage of Chemotherapy With Tyrosine Kinase Inhibitor to Treat Newly Diagnosed ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
8 Medical Research Council Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
9 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
10 An Open-label,Multi-center,Prospective Study of Idarubicin and Etoposide Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
12 Pilot Study for Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia Completed NCT00199095 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone;Idarubicin;Ifosfamide;Methotrexate;Mercaptopurine;VM26;Vincristine
13 Prospective Study of Rituximab Combined With Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia Completed NCT01358253 Phase 4 Cyclophosphamide;Doxorubicin;Vincristine;Dexamethasone;Cytarabine;Methotrexate;Rituximab;6-Mercaptopurine;Prednisone;L-asparaginase
14 Multicenter Trial for Treatment of Acute Lymphoblastic Leukemia in Adults (05/93) Completed NCT00199069 Phase 4 Asparaginase;Vincristine;Daunorubicin, Adriamycin;Cyclophosphamide;Ifosfamide;Cytarabine;Mitoxantrone;Methotrexate;6-Mercaptopurine;6-Thioguanine;VM26;Dexamethasone / Prednisolone
15 Pulses of Vincristine and Dexamethasone During Maintenance in BFM Protocols for Children With Intermediate-Risk Acute Lymphoblastic Leukemia Completed NCT00411541 Phase 4 vincristine;dexamethasone
16 German Multicenter Trial for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years With Rituximab for Improvement of Prognosis in CD20 Positive Standard Risk ALL (Amend 2) Completed NCT00199004 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Vincristine;Daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Adriamycin;Thioguanine;VM26;Rituximab
17 A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
18 Multicenter Trial for Treatment of Acute Lymphocytic Leukemia in Adults (Pilot Study 06/99) Completed NCT00199056 Phase 4 Dexamethasone / Prednisolone;Cyclophosphamide;Methotrexate;Vincristine / Vindesine;Daunorubicin;Asparaginase;G-CSF;Cytarabine;6-Mercaptopurine;VP16;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Ifosfamide
19 Multicenter Trial for Treatment Optimization in T-lymphoblastic Lymphoma in Adults and Adolescents Older Than 15 Years (GMALL T-LBL 1/2004) (Amend 1) Completed NCT00199017 Phase 4 Dexamethasone/Prednisolone;Cyclophosphamide;Vincristine;Daunorubicin;Asparaginase;G-CSF;Mercaptopurine;Cytarabine;Methotrexate;VP16;Vindesine;Adriamycin;Thioguanine;HDARAC;Cladribine
20 The Study on the Pharmacokinetics of Pegylated Recombinant Human Granulocyte Stimulating Factor(PEG-rhG-CSF) in Children and Adolescents Completed NCT02953730 Phase 4 PEG-rhG-CSF
21 ALL-REZ BFM 2002: Protocol for the Treatment of Children With Relapsed Acute Lymphoblastic Leukemia Completed NCT00114348 Phase 4
22 Learning Impairments Among Survivors of Childhood Cancer Completed NCT00576472 Phase 4 Methylphenidate
23 Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7) Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
24 LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive Completed NCT00526305 Phase 4 Vincristine;Daunorubicin;Prednisone;L-Asparaginase;Mitoxantrone;Cytosine Arabinoside;Hydrocortisone;Mercaptopurine;Cyclophosphamide;Dexamethasone
25 Effect of Treatment Using rhIL-11 in Patients With Thrombocytopenia After Chemotherapy for Childhood Acute Lymphoblastic Leukemia Completed NCT02314273 Phase 4 rhIL-11
26 LAL-BR/2001: Study Treatment to Low Risk ALL Completed NCT00526175 Phase 4 Prednisone;Vincristine;Daunorubicin;L-Asparaginase;Cyclophosphamide;Methotrexate;Cytosine Arabinoside;Mercaptopurine;VP-16
27 PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia Completed NCT00494897 Phase 4 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin;Mercaptopurine;Prednisone;Vincristine;Methotrexate
28 LAL-AR-N-2005: Study Treatment for Children High Risk Acute Lymphoblastic Leukemia Completed NCT00526409 Phase 4 Prednisolone;Daunorubicin;Vincristine;L-Asparaginase;Cyclophosphamide;Methotrexate;Cytosine Arabinoside
29 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
31 Plasma Kinetics of Tablet and Liquid Formulations of 6-mercaptopurine in Childhood Acute Lymphoblastic Leukemia. Recruiting NCT01906671 Phase 4 Xaluprine;Puri-Nethol
32 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
33 Allogeneic Stem Cell Transplant for Children and Adolescents With Acute Lymoblastic Leukemia FORUM - Pharmacogenomic Study (add-on Study) Recruiting NCT02670564 Phase 4
34 PROTOCOL FOR THE TREATMENT Acute Lymphoblastic Leukemia With Ph 'NEGATIVE IN ELDERLY PATIENTS (> 55 Years) Recruiting NCT01366898 Phase 4 Dexamethasona, Idarubicine, ARA-C, Methotrexate
35 A Clinical Trial of Decitabine Combined With CODOX-M/IVAC in Relapsed or Refractory T-lymphoblastic Lymphoma Recruiting NCT03558412 Phase 4 Decitabine
36 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor: a Prospective, Multicentre, Randomised Controlled Trial Recruiting NCT02933333 Phase 4
37 Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE Recruiting NCT01491763 Phase 4 Imatinib
38 Treatment Protocol For All Fragile Patients Ph' Negative Over 55 Years Recruiting NCT01358201 Phase 4 vINCRISTINE;Dexamethasone;Methotrexate;Cytosine arabinoside
39 Hematology , Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai, China Recruiting NCT02938741 Phase 4 Anti-human Thymoglobulin;Placebo
40 The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalasemia Major Recruiting NCT02984475 Phase 4 Metformin
41 Vaccinating Children After Chemotherapy for Acute Lymphoblastic Leukemia: A Canadian Immunization Research Network Study Active, not recruiting NCT02447718 Phase 4
42 Treatment of High Risk Adult Acute Lymphoblastic Leukemia Active, not recruiting NCT00853008 Phase 4 Vincristine;Daunorubicin;Prednisone;Mitoxantrone;Cytosine Arabinoside;Dexamethasone;Methotrexate (MTX);Cytarabine;ASP;Mercaptopurine;Teniposide;Hydrocortisone
43 Determinants of Mercaptopurine Toxicity in Paediatric Acute Lymphoblastic Enrolling by invitation NCT03920813 Phase 4 Mercaptopurine
44 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 (Stoss Therapy) in Pediatric Patients Undergoing HSCT to Prevent Vitamin D Deficiency and Insufficiency During Transplant Enrolling by invitation NCT03176849 Phase 4
45 ProphyALL - Pilot Study on Safety of Four Weekly Administrations of 7 mg/kg of Liposomal Amphotericin B (AmBisome®) in Antifungal Primary Prophylaxis Treatment of Elderly Patients With Acute Lymphoblastic Leukemia Undergoing Induction Chemotherapy Within the GMALL-Elderly Protocol Terminated NCT00386997 Phase 4 liposomal amphotericin B (AmBisome®)
46 Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for Acute Lymphocytic Leukemia Terminated NCT00299234 Phase 4 Atomoxetine
47 A Phase-2 Clinical Study to Determine the Efficacy and Safety of Depocyt (Cytarabine Liposome Injection) for the Treatment of CNS Relapse in Adult Patients With Acute Lymphoblastic Leukemia or Very Aggressive Lymphoma Unknown status NCT00199108 Phase 2, Phase 3 Depocyt;Dexamethasone
48 Phase III Study of Vincristine Sulfate Liposome Or Vincristine Sulfate For Injection Combined Chemotherapy as Initial Induction Regimen In Adults Acute Lymphoblastic Leukemia Unknown status NCT02072785 Phase 3 Vincristine Sulfate Liposome;Vincristine Sulfate
49 Randomized Controlled Trial to Test Efficacy of High-Dose Methotrexate Consolidation Therapy for BCR-ABL-Negative Acute Lymphoblastic Leukemia in Adults Unknown status NCT00131027 Phase 3 Cyclophosphamide;Daunorubicin;Vincristine;Prednisolone;L-asparaginase;Cytarabine;Etoposide;Dexamethasone;Methotrexate;Mercaptopurine;Doxorubicin;Methotrexate
50 Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia Unknown status NCT01423747 Phase 3 VP16;VP16, ATG;Fludarabine, OKT3, Treosulfan, Thiotepa;VP16, ATG

Search NIH Clinical Center for Leukemia, Acute Lymphoblastic

Inferred drug relations via UMLS 72 / NDF-RT 51 :

Asparaginase Erwinia chrysanthemi
Asparaginase Escherichia coli
Calaspargase pegol
Idarubicin Hydrochloride

Cell-based therapeutics:

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia, Acute Lymphoblastic cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: precursor cell lymphoblastic leukemia-lymphoma

Genetic Tests for Leukemia, Acute Lymphoblastic

Genetic tests related to Leukemia, Acute Lymphoblastic:

# Genetic test Affiliating Genes
1 Acute Lymphoblastic Leukemia 29
2 Leukemia, Acute Lymphoblastic, Susceptibility to 29

Anatomical Context for Leukemia, Acute Lymphoblastic

MalaCards organs/tissues related to Leukemia, Acute Lymphoblastic:

T Cells, B Cells, Bone, Bone Marrow, Myeloid, Testes, Brain
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Leukemia, Acute Lymphoblastic:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease
3 Blood Hematopoietic Bone Marrow Small Pre B-Cells Affected by disease

Publications for Leukemia, Acute Lymphoblastic

Articles related to Leukemia, Acute Lymphoblastic:

(show top 50) (show all 24681)
# Title Authors PMID Year
FLT3 mutations in childhood acute lymphoblastic leukemia. 9 38 8 71
14670924 2004
First case of aplastic anemia in a Japanese child with a homozygous missense mutation in the NBS1 gene (I171V) associated with genomic instability. 9 38 71
15338273 2004
Mutations in the Nijmegen Breakage Syndrome gene (NBS1) in childhood acute lymphoblastic leukemia (ALL). 9 38 71
11325820 2001
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. 38 71
30643249 2019
RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. 38 8
24413735 2014
Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. 38 8
24076604 2013
A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. 38 71
24013638 2013
Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. 38 8
23263491 2013
Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. 38 8
22237151 2012
Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. 38 8
21892159 2011
PHF6 mutations in T-cell acute lymphoblastic leukemia. 38 8
20228800 2010
Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood. 38 8
20042726 2010
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. 38 8
19838194 2009
Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. 38 8
19684604 2009
Germline genomic variants associated with childhood acute lymphoblastic leukemia. 38 8
19684603 2009
Mutation analysis of the HOX paralogous 4-13 genes in children with acute lymphoid malignancies: identification of a novel germline mutation of HOXD4 leading to a partial loss-of-function. 38 71
15776434 2005
Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. 38 8
15361874 2004
Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. 38 8
9531611 1998
Leukaemia hijacks a neural mechanism to invade the central nervous system. 8
30022166 2018
Histidine catabolism is a major determinant of methotrexate sensitivity. 8
29995852 2018
Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia. 8
29342136 2018
Metabolic gatekeeper function of B-lymphoid transcription factors. 8
28192788 2017
Germline De Novo Mutations in GNB1 Cause Severe Neurodevelopmental Disability, Hypotonia, and Seizures. 71
27108799 2016
Mutations in G protein β subunits promote transformation and kinase inhibitor resistance. 71
25485910 2015
Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. 8
25132549 2014
Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia. 8
25043004 2014
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. 8
22237106 2012
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. 8
21593872 2011
CREBBP mutations in relapsed acute lymphoblastic leukaemia. 8
21390130 2011
Hypermethylation of specific microRNA genes in MLL-rearranged infant acute lymphoblastic leukemia: major matters at a micro scale. 38 88
21116279 2011
Genetic variegation of clonal architecture and propagating cells in leukaemia. 8
21160474 2011
Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia. 38 88
18923441 2009
MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. 38 88
18056805 2007
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. 8
17344859 2007
Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. 71
11442493 2001
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. 71
11290608 2001
Sequence and analysis of the human ABL gene, the BCR gene, and regions involved in the Philadelphia chromosomal translocation. 8
7665185 1995
A new fused transcript in Philadelphia chromosome positive acute lymphocytic leukaemia. 8
2825022 1987
A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia. 8
3543692 1987
Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL. 8
3541203 1987
Bad to the Bone. 17
31340097 2019
Light-chain plasma cell myeloma caused by 14q32/IGH translocation and loss of the other allele. 17
30887274 2019
Hypericin-photodynamic therapy inhibits the growth of adult T-cell leukemia cells through induction of apoptosis and suppression of viral transcription. 17
30782173 2019
Polymorphisms of the gamma-glutamyl hydrolase gene and risk of relapse to acute lymphoblastic leukemia in Mexico. 9 38
20197200 2010
Pharmacogenetic risk factors for altered bone mineral density and body composition in pediatric acute lymphoblastic leukemia. 9 38
20015871 2010
Glucocorticoid receptor knock down reveals a similar apoptotic threshold but differing gene regulation patterns in T-cell and pre-B-cell acute lymphoblastic leukemia. 9 38
20170710 2010
Association between the methylenetetrahydrofolate reductase polymorphisms and risk of acute lymphoblastic leukemia in Serbian children. 9 38
20445408 2010
IL-7 receptor is expressed on adult pre-B-cell acute lymphoblastic leukemia and other B-cell derived neoplasms and correlates with expression of proliferation and survival markers. 9 38
20060740 2010
Genetic inactivation of Ikaros is a rare event in human T-ALL. 9 38
19796813 2010
STAT5 in B cell development and leukemia. 9 38
20227268 2010

Variations for Leukemia, Acute Lymphoblastic

ClinVar genetic disease variations for Leukemia, Acute Lymphoblastic:

6 (show all 36)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 FLT3 NM_004119.2(FLT3): c.2504A> T (p.Asp835Val) single nucleotide variant Pathogenic rs121909646 13:28592641-28592641 13:28018504-28018504
2 FLT3 NM_004119.2(FLT3): c.2503G> T (p.Asp835Tyr) single nucleotide variant Pathogenic rs121913488 13:28592642-28592642 13:28018505-28018505
3 FLT3 NM_004119.2(FLT3): c.1777_1779del (p.Asp593del) deletion Pathogenic rs587776834 13:28608277-28608279 13:28034140-28034142
4 PMS2 NM_000535.7(PMS2): c.1831dup (p.Ile611fs) duplication Pathogenic rs63750250 7:6026565-6026565 7:5986934-5986934
5 ETV6 NM_001987.4(ETV6): c.1153-5_1153-1del short repeat Pathogenic rs786205154 12:12038855-12038859 12:11885921-11885925
6 ETV6 NM_001987.4(ETV6): c.1046T> C (p.Leu349Pro) single nucleotide variant Pathogenic rs786205155 12:12037415-12037415 12:11884481-11884481
7 ACTB NP_001092.1(ACTB): p.Val209Leu protein only Pathogenic
8 PAX5 PAX5, PRO80ARG undetermined variant Pathogenic
9 NBN NM_002485.4(NBN): c.1030C> T (p.Gln344Ter) single nucleotide variant Pathogenic/Likely pathogenic rs767215758 8:90971047-90971047 8:89958819-89958819
10 GNB1 NM_002074.5(GNB1): c.239T> A (p.Ile80Asn) single nucleotide variant Pathogenic/Likely pathogenic rs752746786 1:1737942-1737942 1:1806503-1806503
11 GNB1 NM_002074.5(GNB1): c.227A> G (p.Asp76Gly) single nucleotide variant Pathogenic/Likely pathogenic rs869312821 1:1737954-1737954 1:1806515-1806515
12 NBN NM_002485.4(NBN): c.1903A> T (p.Lys635Ter) single nucleotide variant Pathogenic/Likely pathogenic rs587782545 8:90960063-90960063 8:89947835-89947835
13 NBN NM_002485.4(NBN): c.2140C> T (p.Arg714Ter) single nucleotide variant Pathogenic/Likely pathogenic rs730881864 8:90955525-90955525 8:89943297-89943297
14 NBN NM_002485.4(NBN): c.156_157del (p.Ser53fs) deletion Pathogenic/Likely pathogenic rs767454740 8:90994964-90994965 8:89982736-89982737
15 NBN NM_002485.4(NBN): c.1262T> C (p.Leu421Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs104895032 8:90967646-90967646 8:89955418-89955418
16 NBN NM_002485.4(NBN): c.628G> T (p.Val210Phe) single nucleotide variant Conflicting interpretations of pathogenicity rs61754796 8:90983475-90983475 8:89971247-89971247
17 NBN NM_002485.4(NBN): c.511A> G (p.Ile171Val) single nucleotide variant Conflicting interpretations of pathogenicity rs61754966 8:90990521-90990521 8:89978293-89978293
18 NBN NM_002485.4(NBN): c.1999T> C (p.Ser667Pro) single nucleotide variant Conflicting interpretations of pathogenicity rs587780091 8:90958439-90958439 8:89946211-89946211
19 NBN NM_002485.4(NBN): c.425A> G (p.Asn142Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs769414 8:90993017-90993017 8:89980789-89980789
20 NBN NM_002485.4(NBN): c.595C> T (p.Pro199Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs587780097 8:90983508-90983508 8:89971280-89971280
21 NBN NM_002485.4(NBN): c.119C> T (p.Ser40Leu) single nucleotide variant Uncertain significance rs587781530 8:90995002-90995002 8:89982774-89982774
22 NBN NM_002485.4(NBN): c.456G> A (p.Met152Ile) single nucleotide variant Uncertain significance rs201816949 8:90992986-90992986 8:89980758-89980758
23 NBN NM_002485.4(NBN): c.505C> T (p.Arg169Cys) single nucleotide variant Uncertain significance rs182756889 8:90990527-90990527 8:89978299-89978299
24 NBN NM_002485.4(NBN): c.2149A> T (p.Thr717Ser) single nucleotide variant Uncertain significance rs587780093 8:90955516-90955516 8:89943288-89943288
25 HOXD4 NM_014621.3(HOXD4): c.242A> T (p.Glu81Val) single nucleotide variant Uncertain significance rs104893636 2:177016603-177016603 2:176151875-176151875
26 NBN NM_002485.4(NBN): c.1034G> T (p.Gly345Val) single nucleotide variant Uncertain significance rs587780089 8:90971043-90971043 8:89958815-89958815
27 NBN NM_002485.4(NBN): c.503G> A (p.Gly168Glu) single nucleotide variant Uncertain significance rs1554566728 8:90990529-90990529 8:89978301-89978301
28 NBN NM_002485.4(NBN): c.11T> G (p.Leu4Arg) single nucleotide variant Uncertain significance rs748090667 8:90996779-90996779 8:89984551-89984551
29 NBN NM_002485.4(NBN): c.431C> T (p.Thr144Ile) single nucleotide variant Uncertain significance rs1554567906 8:90993011-90993011 8:89980783-89980783
30 NBN NM_002485.4(NBN): c.775G> A (p.Glu259Lys) single nucleotide variant Uncertain significance rs201559159 8:90982713-90982713 8:89970485-89970485
31 NBN NM_002485.4(NBN): c.683T> G (p.Ile228Arg) single nucleotide variant Uncertain significance rs777460725 8:90983420-90983420 8:89971192-89971192
32 NBN NM_002485.4(NBN): c.2215C> G (p.Leu739Val) single nucleotide variant Uncertain significance rs370058152 8:90949273-90949273 8:89937045-89937045
33 NBN NM_002485.4(NBN): c.340G> T (p.Val114Phe) single nucleotide variant Uncertain significance rs771034958 8:90993102-90993102 8:89980874-89980874
34 NBN NM_002485.4(NBN): c.361G> C (p.Asp121His) single nucleotide variant Uncertain significance rs777916019 8:90993081-90993081 8:89980853-89980853
35 PAX5 NM_016734.3(PAX5): c.435G> C (p.Gln145His) single nucleotide variant Uncertain significance 9:37006510-37006510 9:37006513-37006513
36 NBN NM_002485.4(NBN): c.390A> G (p.Gln130=) single nucleotide variant Uncertain significance 8:90993052-90993052 8:89980824-89980824

UniProtKB/Swiss-Prot genetic disease variations for Leukemia, Acute Lymphoblastic:

# Symbol AA change Variation ID SNP ID
1 PAX5 p.Gly183Ser VAR_070682 rs398123063

Copy number variations for Leukemia, Acute Lymphoblastic from CNVD:

7 (show top 50) (show all 2943)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13316 1 1 117600000 Loss Acute lymphoblastic leukemia
2 13371 17 1 22200000 Deletion TP53 Acute lymphoblastic leukemia
3 13410 1 1 2300000 Copy number Acute lymphoblastic leukemia
4 13773 1 1 35400000 Duplication Acute lymphoblastic leukemia
5 13788 1 1 40300000 Duplication Acute lymphoblastic leukemia
6 13790 1 1 46500000 Gain Acute lymphoblastic leukemia
7 13836 12 10000000 12600000 Deletion ETV6 Acute lymphoblastic leukemia
8 13906 1 100818677 103024856 Loss DPH5 Acute lymphoblastic leukemia
9 13907 1 100818677 103024856 Loss EXTL2 Acute lymphoblastic leukemia
10 13908 1 100818677 103024856 Loss OLFM3 Acute lymphoblastic leukemia
11 13909 1 100818677 103024856 Loss S1PR1 Acute lymphoblastic leukemia
12 13910 1 100818677 103024856 Loss SLC30A7 Acute lymphoblastic leukemia
13 13911 1 100818677 103024856 Loss VCAM1 Acute lymphoblastic leukemia
14 13991 1 102370195 102561809 Deletion Acute lymphoblastic leukemia
15 14292 1 106673274 107678605 Loss NTNG1 Acute lymphoblastic leukemia
16 14293 1 106673274 107678605 Loss PRMT6 Acute lymphoblastic leukemia
17 14369 1 107716342 144004701 Loss ADAM30 Acute lymphoblastic leukemia
18 14370 1 107716342 144004701 Loss ADORA3 Acute lymphoblastic leukemia
19 14371 1 107716342 144004701 Loss AFARP1 Acute lymphoblastic leukemia
20 14372 1 107716342 144004701 Loss AHCYL1 Acute lymphoblastic leukemia
21 14373 1 107716342 144004701 Loss AKNAD1 Acute lymphoblastic leukemia
22 14374 1 107716342 144004701 Loss ALX3 Acute lymphoblastic leukemia
23 14375 1 107716342 144004701 Loss AMIGO1 Acute lymphoblastic leukemia
24 14376 1 107716342 144004701 Loss AMPD1 Acute lymphoblastic leukemia
25 14377 1 107716342 144004701 Loss AMPD2 Acute lymphoblastic leukemia
26 14378 1 107716342 144004701 Loss AP4B1 Acute lymphoblastic leukemia
27 14379 1 107716342 144004701 Loss ATP1A1 Acute lymphoblastic leukemia
28 14380 1 107716342 144004701 Loss ATP5F1 Acute lymphoblastic leukemia
29 14381 1 107716342 144004701 Loss ATXN7L2 Acute lymphoblastic leukemia
30 14382 1 107716342 144004701 Loss BCAS2 Acute lymphoblastic leukemia
31 14383 1 107716342 144004701 Loss BCL2L15 Acute lymphoblastic leukemia
32 14384 1 107716342 144004701 Loss C1orf103 Acute lymphoblastic leukemia
33 14385 1 107716342 144004701 Loss C1orf152 Acute lymphoblastic leukemia
34 14386 1 107716342 144004701 Loss C1orf161 Acute lymphoblastic leukemia
35 14387 1 107716342 144004701 Loss C1orf162 Acute lymphoblastic leukemia
36 14388 1 107716342 144004701 Loss C1orf183 Acute lymphoblastic leukemia
37 15383 1 115048600 115061038 Copy number NRAS Acute lymphoblastic leukemia
38 15429 1 115400000 222100000 Gain Acute lymphoblastic leukemia
39 15832 1 119869201 120436800 Loss HMGCS2 Acute lymphoblastic leukemia
40 15833 1 119869201 120436800 Loss NBPF7 Acute lymphoblastic leukemia
41 15834 1 119869201 120436800 Loss NOTCH2 Acute lymphoblastic leukemia
42 15835 1 119869201 120436800 Loss PHGDH Acute lymphoblastic leukemia
43 15836 1 119869201 120436800 Loss REG4 Acute lymphoblastic leukemia
44 15837 1 119869201 120436800 Loss ZNF697 Acute lymphoblastic leukemia
45 15979 1 120700000 169100000 Loss CREG1 Acute lymphoblastic leukemia
46 16426 1 124300000 247249719 Deletion Acute lymphoblastic leukemia
47 16427 1 124300000 247249719 Duplication Acute lymphoblastic leukemia
48 16474 1 125000000 249250621 Copy number Acute lymphoblastic leukemia
49 16502 1 12600000 16100000 Deletion Acute lymphoblastic leukemia
50 16592 1 128000000 185104377 Copy number Acute lymphoblastic leukemia

Expression for Leukemia, Acute Lymphoblastic

Search GEO for disease gene expression data for Leukemia, Acute Lymphoblastic.

Pathways for Leukemia, Acute Lymphoblastic

Pathways related to Leukemia, Acute Lymphoblastic according to KEGG:

# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

Pathways related to Leukemia, Acute Lymphoblastic according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.51 MIR223 MIR203A MIR155 MIR152 MIR128-1
2 10.3 FLT3 ETV6

GO Terms for Leukemia, Acute Lymphoblastic

Biological processes related to Leukemia, Acute Lymphoblastic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gene silencing by miRNA GO:0035195 9.17 MIR708 MIR223 MIR203A MIR196B MIR155 MIR152

Molecular functions related to Leukemia, Acute Lymphoblastic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.02 MIR223 MIR203A MIR155 MIR152 MIR128-1

Sources for Leukemia, Acute Lymphoblastic

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
71 Tocris
73 UMLS via Orphanet
Loading form....